Why are 750 pharma leaders coming to Pharma Japan 2021?

Who you will meet:

pfizer's Logo
roche's Logo
novartis's Logo
johnson_johnson's Logo

sanofi's Logo

abbvie's Logo
gsk_logo's Logo
janssen's Logo

bms's Logo
astra_zeneca's Logo

lilly's Logo
bayer's Logo

novo_nordisk's Logo
takeda's Logo
boehringer_ingelheim's Logo

allergan's Logo

astellas's Logo
biogen's Logo
csl's Logo
Daiichi Sankyo's Logo

otsuka_us's Logo
UCB's Logo
Eisai's Logo
LEO Pharma's Logo

ViiV Healthcare's Logo

Representatives include:
  • VP Sales and Marketing
  • Chief Marketing Officer
  • Digital & Multichannel Lead
  • VP, Medical Affairs
  • Director of Strategic Marketing
  • Global Digital Marketing Leader
  • Head of Medical Affairs
  • Global Head of Digital Excellence
  • Head of Customer Engagement
  • Head of Innovation, Data and CX
  • VP R&D
  • Director, Clinical Operations
  • Director, Digital Health
  • Director, Clinical Trials
  • Director, Patient Advocacy & Strategic Partnerships
  • Director, Open Innovation

Our essential themes for 2021:

  • A new era of collaboration, a new era of medical innovation: Ensure a more sustainable future by partnering with stakeholders across healthcare to better represent diverse patient populations, communicate the value of new medicines, and navigate regulatory pathways
  • Achieve unprecedented customer engagement: Integrate agile operating models to enable close-loop marketing, linking insights from all channels to better inform digital investment, personalize content for HCPs and patients, and define new hybrid-field team strategies
  • Adoption, acceptance and next: Evolve your role as Medical Affairs. It’s been more than 5 years since medical affairs have gained their citizenship in Japan’s pharma industry. Examine the results of outcomes medical affairs have delivered and gain insights to build a new model by ensuring its role and accountability reflects transformed environmental changes and expectations.
  • Empower Medical Affairs to deliver new stakeholder value: Meet evolving HCP and patient needs by honing the role of the MSL in external engagement, upskilling and capability building for new digital norms, and redefining performance measures they reflect the transforming healthcare environment
  • Scale digital-trials to ensure patient-preferred trials: Meet patient unmet needs and accelerate regulatory approval by creating an integrated evidence approach across your trials - use real-world evidence (RWE) in combination with AI advancements to discover new insights and support trial design, execution, and outcomes

Who you’ll meet when you sponsor or exhibit

Real decision-makers

Other events say they attract senior executives - people with clout, budget, ideas and a mission. We really mean it.

Real diversity

Pharma Japan attracts a variety of job titles, cultures and opinions create a rich tapestry.

Here to help

Get in touch with the Reuters Events team